Skip to content

A Randomized Controlled Clinical Study to Evaluate the Effect of Chandravaleha Compared to Sarpagandha Ghanavati in the Management of Essential HypertensionERTENSION.

A RANDOMIZED CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFECT OF CHANDRAVALEHA OVER SARPAGANDHA GHANAVATI IN THE MANAGEMENT OF PITTAVRUTA UDANA VATA WITH SPECIAL REFERANCE TO ESSENTIAL HYPERTENSION. - NIL

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108864
Enrollment
40
Registered
2026-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

Dr Vishal Mahadev Khot
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects presenting with signs and symptoms of Pittavruta Udana Vata such as Bhrama and Klama 2 Subjects presenting with cardinal signs and symptoms of Essential Hypertension such as Dizziness Fatigue Headache and Palpitation 3 Subjects belonging to the age group between 30 to 70 years inclusive of both genders 4 Confirmed diagnosis of Essential Hypertension with systolic blood pressure between 140 to 159 mmHg and diastolic blood pressure between 90 to 99 mmHg corresponding to Stage 1 Hypertension as per JNC VII classification of blood pressure 5 Subjects who are willing to participate in the study and provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Subjects having secondary Hypertension due to secondary disease like Renal failure, Endocrinal disorders, Neurogenic causes etc. 2. Subjects having any complications of Hypertension and history of cardiac conditions. 3. Subjects suffering with Diabetes mellitus. 4. Any other serious medical and surgical ill subjects. 5. Pregnant women and Lactating women. 6. Subjects with alcohol dependency and drug dependency.

Design outcomes

Primary

MeasureTime frame
Reduction in systolic and diastolic blood pressure measured using a standardized sphygmomanometer at baseline mid treatment and end treatment and analyzed according to JNC VII classification of blood pressureTimepoint: 1st 15th 30th 45th day

Secondary

MeasureTime frame
Reduction of sign and symptoms like Dizziness, Fatigue, Headache and Palpitation with special reference to Essential Hypertension.Timepoint: Baseline, Mid-treatment, and End-treatment

Countries

India

Contacts

Public ContactDr Vishal Mahadev Khot

DGM Ayurvedic Medicle College and Hospital Gadag

hardikasnb@gmail.com9886916367

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026